Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dog Diseases | 11 | 2022 | 86 | 1.580 |
Why?
|
| Osteosarcoma | 4 | 2022 | 82 | 0.720 |
Why?
|
| Bone Neoplasms | 4 | 2022 | 259 | 0.680 |
Why?
|
| Hemangiosarcoma | 2 | 2013 | 25 | 0.650 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2017 | 74 | 0.560 |
Why?
|
| Cyclophosphamide | 2 | 2017 | 270 | 0.500 |
Why?
|
| Cats | 1 | 2017 | 231 | 0.500 |
Why?
|
| Dogs | 13 | 2023 | 458 | 0.460 |
Why?
|
| Abetalipoproteinemia | 1 | 2013 | 4 | 0.410 |
Why?
|
| Lymphoma | 2 | 2013 | 237 | 0.400 |
Why?
|
| Doxorubicin | 3 | 2007 | 401 | 0.280 |
Why?
|
| Splenic Neoplasms | 1 | 2007 | 5 | 0.260 |
Why?
|
| Etoposide | 1 | 2007 | 168 | 0.250 |
Why?
|
| Lymphoma, B-Cell | 1 | 2007 | 140 | 0.230 |
Why?
|
| Nose Neoplasms | 1 | 2004 | 22 | 0.210 |
Why?
|
| Sarcoma | 2 | 2023 | 207 | 0.210 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2023 | 6 | 0.200 |
Why?
|
| Brain Death | 1 | 2023 | 60 | 0.190 |
Why?
|
| Antineoplastic Agents | 4 | 2010 | 2214 | 0.190 |
Why?
|
| Cisplatin | 1 | 2004 | 345 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 131 | 0.180 |
Why?
|
| Administration, Oral | 3 | 2017 | 866 | 0.180 |
Why?
|
| Analgesia | 1 | 2022 | 106 | 0.170 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2000 | 56 | 0.150 |
Why?
|
| Tobacco Smoking | 1 | 2019 | 27 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 1 | 2023 | 343 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2000 | 131 | 0.150 |
Why?
|
| Veterinary Medicine | 1 | 2019 | 11 | 0.150 |
Why?
|
| Smokers | 1 | 2019 | 138 | 0.140 |
Why?
|
| Half-Life | 2 | 2017 | 155 | 0.140 |
Why?
|
| Animals | 15 | 2023 | 38030 | 0.140 |
Why?
|
| Vaping | 1 | 2019 | 74 | 0.140 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2019 | 110 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 1 | 2017 | 116 | 0.130 |
Why?
|
| Pain | 2 | 2022 | 789 | 0.130 |
Why?
|
| Biological Availability | 1 | 2017 | 145 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 172 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2017 | 331 | 0.120 |
Why?
|
| Hospice Care | 1 | 2019 | 227 | 0.110 |
Why?
|
| Biomarkers | 1 | 2007 | 4295 | 0.110 |
Why?
|
| Acanthocytes | 1 | 2013 | 1 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 572 | 0.100 |
Why?
|
| Fas Ligand Protein | 1 | 2012 | 61 | 0.090 |
Why?
|
| Anemia | 1 | 2013 | 191 | 0.090 |
Why?
|
| Italy | 2 | 2023 | 116 | 0.090 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2010 | 7 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2012 | 316 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 143 | 0.060 |
Why?
|
| Lomustine | 1 | 2006 | 17 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 164 | 0.060 |
Why?
|
| Mycosis Fungoides | 1 | 2006 | 63 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 1471 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2004 | 1266 | 0.050 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2006 | 143 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2004 | 1374 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 222 | 0.050 |
Why?
|
| Anal Gland Neoplasms | 1 | 2003 | 1 | 0.050 |
Why?
|
| Female | 7 | 2023 | 78845 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2004 | 189 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2023 | 39 | 0.050 |
Why?
|
| Male | 6 | 2019 | 72843 | 0.050 |
Why?
|
| Colorado | 2 | 2019 | 4554 | 0.040 |
Why?
|
| Attitude | 1 | 2023 | 259 | 0.040 |
Why?
|
| Carcinoma | 1 | 2003 | 225 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2006 | 583 | 0.040 |
Why?
|
| Extremities | 1 | 2022 | 141 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2023 | 430 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 420 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 641 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2000 | 121 | 0.040 |
Why?
|
| Education, Veterinary | 1 | 2019 | 5 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 534 | 0.040 |
Why?
|
| Pets | 1 | 2019 | 26 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 345 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 849 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17291 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 925 | 0.030 |
Why?
|
| Universities | 1 | 2019 | 445 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2019 | 440 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1734 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 2865 | 0.020 |
Why?
|
| Mutation | 1 | 2023 | 4075 | 0.020 |
Why?
|
| Curriculum | 1 | 2019 | 1070 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 244 | 0.020 |
Why?
|
| Brain | 1 | 2023 | 2947 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2022 | 11772 | 0.020 |
Why?
|
| Neoplasms | 1 | 2006 | 2906 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 141 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 226 | 0.020 |
Why?
|
| Piperidines | 1 | 2010 | 222 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 5905 | 0.020 |
Why?
|
| Time Factors | 2 | 2010 | 7123 | 0.020 |
Why?
|
| Survivors | 1 | 2010 | 523 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 6066 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 738 | 0.010 |
Why?
|
| Pyridines | 1 | 2010 | 609 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 2090 | 0.010 |
Why?
|
| Vincristine | 1 | 2006 | 142 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 2121 | 0.010 |
Why?
|
| Prednisone | 1 | 2006 | 224 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 782 | 0.010 |
Why?
|
| Anal Sacs | 1 | 2003 | 1 | 0.010 |
Why?
|
| Humans | 3 | 2023 | 145475 | 0.010 |
Why?
|
| Apocrine Glands | 1 | 2003 | 5 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 2440 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 592 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 387 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2006 | 870 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 22530 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 919 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 1140 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1963 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 2664 | 0.000 |
Why?
|